March 14, 2019
Promovendus (1,0 fte), FHML/School for Cardiovascular Diseases/CARIM, Biochemistry/Dr I. Dijkgraaf
PhD student position in chemical and structural biology: targeting and unraveling the blood coagulation cascade by a tick protein
Tissue factor (TF) is the initiator of the extrinsic coagulation cascade and a risk factor for thrombotic disease. Uncontrolled thrombin generation and blood clot formation is the underlying cause of most heart attacks, strokes, deep vein thromboses (DVT), and pulmonary embolisms (PE). With that, thrombosis is a leading cause of death and disability worldwide. In this project, a tick-derived TF-binding protein will be investigated. Structure-activity relationship studies (SARs) of this protein, TF-binding properties, and its molecular interaction in thrombosis will be assessed using solution NMR, Surface Plasmon Resonance (SPR), solution-phase affinity assays and molecular imaging techniques. Therefore, this tick protein, TF, and derivatives thereof will be synthesized using solid-phase peptide synthesis, native chemical ligation, and biological expression techniques.
February 18, 2019 and March 14, 2019
Promovendus (1,0 fte), FHML/School for Cardiovascular Diseases/CARIM, Epidemiologie/Dr Frank de Vries
We zoeken bij voorkeur een nieuwsgierige apotheker, arts of gezondheidswetenschapper
De kandidaat gaat onderzoek doen naar het ontwikkelen van nieuwe methodes om de gepersonaliseerde behandeling van patiënten met diabetes te verbeteren. Hiervoor zullen zowel standaard statistische methodes gebruikt worden als artificiële intelligentie technieken.
Een deel van het onderzoek wordt uitgevoerd in Denemarken (Aalborg) en mogelijk Spanje (Madrid). De promovendus zal gedurende een periode van 6-12 maanden onderzoek in het buitenland uitvoeren.
Het onderzoek leidt tot wetenschappelijke publicaties die de basis vormen van een Engelstalig wetenschappelijk proefschrift.
February 11, 2019
VIMM and at the Dept of Biology of the University of Padua, Italy
3-year fully funded PhD student position is available in the lab of Dr. Luca Scorrano at VIMM and at the Dept of Biology of the University of Padua
A 3-year fully funded PhD student position is available in the lab of Dr. Luca Scorrano at VIMM and at the Dept of Biology of the University of Padua to exploit Opa1 overexpression in experimental therapy of mitochondrial disorders. The successful candidate will apply to, and be enrolled in the PhD school in Biosciences of the U. of Padua Dept. of Biology (https://dottorato.biologia.unipd.it/), starting from October 1st, 2019 (nonnegotiable date).
The Scorrano lab works on mitochondrial dynamics & interorganellar contact sites, from their basic tenets (e.g. Frezza et al., Cell 2006; Cipolat et al, Cell 2006; Cereghetti et al, PNAS 2008; deBrito&Scorrano, Nature 2008; Gomes et al., Nat Cell Biol 2011; Cogliati et al., Cell 2013; Naon et al., PNAS 2016; Quintana Cabrera et al., Nat. Commun 2018), to their role in disease (e.g. Costa et al., EMBO Mol. Med 2010; Cerqua et al., EMBO Rep 2010; Kasahara et al., Science 2013; Varanita et al, Cell Metab 2015; Pernas et al., Cell Metab 2018). In a collaboration with Dr. Massimo Zeviani’s lab (MBU MRC, Cambridge) we provided the proof of principle that Opa1 overexpression can correct models of mitochondrial disorders (Civiletto, Varanita et al., Cell Metab 2015).
Thanks to a project funded by Muscular Dystrophy Association USA, we now wish to epigenetically modulate Opa1 levels in cellular and mouse models of mitochondrial disorders to elucidate if this approach can correct mitochondrial dysfunction in vitro and muscle atrophy in vivo.
We are looking for an energetic, brilliant, highly motivated junior fellow, with some training in molecular and cell biology and biochemistry. Experience with in vivo models would be considered a plus. We require a MSc degree (or a 4 years BSc degree) in a relevant field, the ability to work independently with limited supervision and to interact with colleagues with different backgrounds. The successful candidate will join an established, multicultural group of 15 talented colleagues coming from 3 different continents, tackling various basic aspects of mitochondrial dynamics and of interorganellar contact sites.
We offer state-of-the-art labs and facilities, a thriving environment, an exciting research project and multiple occasions of interaction with world leaders in mitochondrial pathophysiology for which Padua is known as an international hub. We foster professional growth of PhD students and strive for their success. Padua is a beautiful city with a thriving cultural scene, close to the seaside, Venice and the Dolomites. Salary will follow the U. of Padua PhD salary scale (net: 1150€/month).
Interested candidates shall email Luca Scorrano (email@example.com) a cover letter, a CV, and names and emails of two references. Shortlisted candidates will be invited for a two-day on-site interview and the successful candidate will be assisted in the application process to the PhD School.
February 1, 2019
Promovendus FHML/School for Cardiovascular Diseases/CARIM - Biomedical Engineering
PhD candidate on Computational Modeling of Cardiac Electromechanics: bridging the gap between electrics and mechanics in the human heart
We are looking for a highly motivated PhD candidate to join our multidisciplinary and translational research team, who is eager to be challenged and passionate to use computational modeling to solve the complex puzzle of sudden cardiac death in the young.
In the young (<40 years), sudden cardiac death (SCD) is often the first manifestation of a genetic cardiac disease causing lethal arrhythmias. Both male gender and physical exercise are known risk factors for SCD in this vulnerable population. Current mechanistic understanding of how gender-related and environmental factors, such as exercise, interact with a pro-arrhythmic substrate and trigger life-threatening arrhythmias is limited. This lack of knowledge makes the identification of those at risk for SCD extremely difficult. The EMPATHY project aims to unravel the complex pro-arrhythmic electro-mechanical interactions in the apparently healthy yet vulnerable hosts of genetic cardiac diseases by combining three different but highly complementary scientific fields, being clinical cardiac imaging (OSLO partner), genetics and cellular electrophysiology (MILAN partner), and multi-scale computational modelling (MAASTRICHT partner). We expect that the integrative EMPATHY approach will reveal novel genetic and electro-mechanical signatures of arrhythmogenic diseases, enabling earlier disease recognition, personalized therapeutic intervention, and effective prevention of SCD in the young.
January 30, 2019
The Institute for Molecular Cardiovascular Research (IMCAR), Medical Faculty of RWTH Aachen University
PhD Candidate (m/f) in Immune-Lipid crosstalk
It has been recently shown that chronic kidney disease (CKD) patients have an increased risk for cardiovascular disease (CVD), although the precise underlying mechanisms remain elusive.
Candidates will perform research to explore the contribution of a novel mechanism of immune-lipid crosstalk, which might explain at least partly the observed increased CVD risk in CKD-patients. Hereby, the focus will be to investigate the interference of high-density lipoproteins (HDL) and other lipids with the chemokine-receptor signaling and its functional consequences.
Candidates will be trained in a wide variety of both in-vitro and in-vivo (mouse) models. The working language of the group is English.
The successful candidate has the opportunity to pursue a doctoral degree. The position is initially funded until 31st December 2021 with the option of extension. The salary corresponds to level 65% of 13 TV-L. Interested candidates should send a brief motivation letter, CV and the names of two references by 15th March 2019 to firstname.lastname@example.org.
The RWTH Aachen University is certified as a family-friendly university and offers a dual career program for partner hiring. We particularly welcome and encourage applications from women, disabled people and ethnic minority groups, recognizing they are underrepresented across RWTH Aachen University. The principles of fair and open competition apply and appointments will be made on merit.
October 29, 2018
Research project: Electronic Healthcare Databases and Pharmaco-Epidemiology (unpaid position)
ABOUT THE SUPERVISORS:
Dr. Frank de Vries started a PhD in pharmacoepidemiology at Utrecht University in 2002 on side effects of use of inhaled corticosteroids. Since then, he has worked for the Medicine and Healthcare products Regulatory Agency. He has obtained several research grants and prizes, including the Swierenga award for respiratory disease, an 'NWO Veni' fellowship and the Kohn prize from the UK National Osteoporosis Foundation. His work has been published in various journals including JAMA, the NEJM & BMJ.
He currently works as a hospital pharmacist in the Maastricht University Medical Centre+. He is a member of the Clinical Epidemiology program at School CAPHRI in Maastricht and is on secondmend at the Utrecht Institute for Pharmaceutical Sciences, The Netherlands. He is a visiting scientist at the MRC Lifecourse Epidemiology Unit in Southampton, UK.
Research activities mainly focus on patients with respiratory disease, cardiovascular disease and movement disorders.
ABOUT THE RESEARCH GROUP:
The group is comprised of 6-8 postdocs and 10-15 PhD students. We have an inhouse statistician and can provide supervision in data management, programming and scientific writing. Our group has access to the world's largest electronic healthcare databases and registries such as the UK clinical practice research datalink (n=15 million), the full country of Denmark (n=5.5 million) and the PHARMO Record Linkage System.
All (former) PhD students are currently employed at pharmaceutical companies, academia, drug regulators, health insurance institutions, hospitals or pharmacies.
WORK FIELD OF THE PROPOSED PROJECT:
Pharmacoepidemiology studies the use of drugs and their effects in large numbers of people after market authorization. It overcomes limitations from premarketing randomised clinical drug trials (RCTs), which are not representative of patients in real life clinical care, and which do not allow studying rare (with frequencies ≥0.1%) or long-term severe side effects. Typical pharmaco-epidemiological studies use advanced epidemiological methods to study large electronic healthcare databases (EHDs) with medical records of millions of patients for effectiveness and safety of drugs. Regulatory authorities such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) assess the risk/benefit balance of medicines to decide whether their market authorisation may be restricted or completely withdrawn. Regulatory review is supported by evidence from clinical trials and pharmacoepidemiological studies that are either published, conducted voluntary or upon the regulator´s request by manufacturers of medicines (post-authorisation safety studies [PASS]). A PASS is defined in EU Directive 2001/83/EC. PASS studies will then be assessed by the EMA’s Pharmacovigilance Risk Assessment Committee , which recommends on the maintenance of the terms of the marketing authorization. This is then forwarded to the Committee for Medicinal Products for Human Use for final decision making.
MAIN RESEARCH QUESTION, SUBQUESTIONS AND AIM(S):
With access to billions of medical and prescribing / dispensing records, we can address billions of research questions. To prospective students who bring their own funding, we are quit flexible to discuss details and personal goals.
RESEARCH DESIGN AND METHODS:
Cohort studies, time-varying Cox regression analysis and occasionally case-control and drug utilization studies.
Manuscript writing, statistical programming, SAS programming, medical literature review, study design. We expect you to regularly join our journal club and provide supervision / teaching activities to other students (MSc and PhD). In contrast to most other PhD projects, our data is readily available and you can start analysing from the first day in the office, should a study protocol already have been approved.
A full PhD thesis with 6-8 original scientific articles, a general introduction and a discussion. According to recent interviews with epidemiology executives at large pharmaceutical companies, contract research organisations and regulators, this training will make you perfectly suited for a role in their departments.
Previous PhD students had completed their thesis within 1.5 - 5 years. We offer an environment in which 1.5 years is possible, should you have the right skills and attitude.
COMPETENCES THE APPLICANT NEEDS TO HAVE OR ACQUIRE FOR THE PROJECT:
1. A strong foundation in epidemiology.
2. English writing, reading and speaking skills (CFER C1+ level or equivalent).
3. A background in medicine, pharmacy, epidemiology, statistics, economics or health informatics.
1. Medical Doctor or Pharmacist by training
2. Computer programming skills, preferably SAS
phone number secretariat: +31(0)43-3871881